Published in Am J Respir Crit Care Med on May 15, 2014
Macrolide antibiotics for prevention of chronic obstructive pulmonary disease exacerbations: are we there yet? Am J Respir Crit Care Med (2014) 2.00
Macrolide antibiotics and the risk of ventricular arrhythmia in older adults. CMAJ (2016) 1.43
Bronchiectasis in the Last Five Years: New Developments. J Clin Med (2016) 0.81
Azithromycin use in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis (2015) 0.78
Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization. Antimicrob Agents Chemother (2014) 0.78
The Value of Macrolide-Based Regimens for Community-Acquired Pneumonia. Curr Infect Dis Rep (2015) 0.76
Cardiac risks associated with antibiotics: azithromycin and levofloxacin. Expert Opin Drug Saf (2014) 0.76
Role of Ureaplasma Respiratory Tract Colonization in Bronchopulmonary Dysplasia Pathogenesis: Current Concepts and Update. Clin Perinatol (2015) 0.76
The cardiovascular safety of azithromycin. CMAJ (2014) 0.76
Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias. Curr Cardiol Rev (2016) 0.75
Drug-induced prolongation of the QT interval. N Engl J Med (2004) 10.96
Azithromycin for prevention of exacerbations of COPD. N Engl J Med (2011) 8.66
Azithromycin and the risk of cardiovascular death. N Engl J Med (2012) 8.18
Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med (2004) 6.21
MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell (1999) 5.49
Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol (2006) 5.39
Use of azithromycin and death from cardiovascular causes. N Engl J Med (2013) 4.69
What clinicians should know about the QT interval. JAMA (2003) 4.45
Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA (2003) 4.44
The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med (1992) 3.92
U.S. outpatient antibiotic prescribing, 2010. N Engl J Med (2013) 3.49
Azithromycin for the secondary prevention of coronary events. N Engl J Med (2005) 3.42
Low penetrance in the long-QT syndrome: clinical impact. Circulation (1999) 3.14
Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol (1998) 3.13
Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA (1993) 3.01
Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation (2002) 2.98
Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation (1997) 2.95
Long QT syndromes and torsade de pointes. Lancet (1999) 2.70
Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med (Berl) (2004) 2.68
Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol (1992) 2.63
Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ (2013) 2.43
The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis (1988) 2.42
"Lies, damned lies ..." and observational studies in comparative effectiveness research. Am J Respir Crit Care Med (2013) 2.42
Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes. Pharmacotherapy (2001) 2.33
Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med (2013) 2.25
Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation (1996) 2.13
Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf (2001) 2.02
Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. Heart Rhythm (2007) 1.93
Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J (1999) 1.92
Antibiotic therapy after acute myocardial infarction: a prospective randomized study. Circulation (2003) 1.84
Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation (1996) 1.79
KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation (1997) 1.76
Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol (2000) 1.74
Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors. J Interv Card Electrophysiol (2007) 1.65
Cardiac actions of erythromycin: influence of female sex. JAMA (1998) 1.53
Intersubject and dose-related variability after intravenous administration of erythromycin. Br J Clin Pharmacol (1980) 1.39
Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther (2002) 1.39
Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol (1996) 1.34
Latent genetic backgrounds and molecular pathogenesis in drug-induced long-QT syndrome. Circ Arrhythm Electrophysiol (2009) 1.33
A case of QT-interval prolongation precipitated by azithromycin. N Z Med J (2003) 1.30
Impact of sex and gonadal steroids on prolongation of ventricular repolarization and arrhythmias induced by I(K)-blocking drugs. Circulation (2001) 1.30
Azithromycin-induced QT prolongation in elderly patient. Acta Biomed (2006) 1.23
[Torsade de pointes and cardiorespiratory arrest induced by azithromycin in a patient with congenital long QT syndrome]. Med Clin (Barc) (2001) 1.22
QT prolongation associated with azithromycin/amiodarone combination. Pacing Clin Electrophysiol (2001) 1.21
Polymorphic ventricular tachycardia with a normal QT interval following azithromycin. Pacing Clin Electrophysiol (2005) 1.19
Reduced repolarization reserve in ventricular myocytes from female mice. Cardiovasc Res (2002) 1.14
Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Drug Saf (2004) 1.13
Recurrent ventricular tachycardia associated with QT prolongation after mitral valve replacement and its association with intravenous administration of erythromycin. Am J Cardiol (1984) 1.11
QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: a prospective evaluation and review of the literature. Pharmacotherapy (1996) 1.09
Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. Antimicrob Agents Chemother (2000) 1.06
Comparative pharmacokinetics of macrolides. J Antimicrob Chemother (1987) 1.05
Long Q-T syndrome associated with oral erythromycin used in preoperative bowel preparation. Anesth Analg (1997) 1.03
Effect of erythromycin on ventricular arrhythmias and ventricular repolarization in idiopathic long QT syndrome. Am J Cardiol (1987) 1.03
Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation (1995) 1.02
Torsades de pointes associated with drugs and toxins: recognition and management. Am Heart J (1987) 1.01
Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation (2002) 0.96
Amiodarone and torsade de pointes. Ann Intern Med (1989) 0.95
QT prolongation and recurrent "torsades de pointes" during erythromycin lactobionate infusion. Am J Cardiol (1986) 0.92
[Electrophysiological study of pro-arrhythmogenic effects of erythromycin]. Arch Mal Coeur Vaiss (1988) 0.90
Treatment with clarithromycin prior to coronary artery bypass graft surgery does not prevent subsequent cardiac events. Clin Infect Dis (2005) 0.90
Testosterone diminishes the proarrhythmic effects of dofetilide in normal female rabbits. Circulation (2002) 0.90
Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism. Am J Med (1990) 0.90
Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy. N Engl J Med (1988) 0.89
Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation (1993) 0.89
Torsades de pointes induced by antibiotics. Eur J Intern Med (2006) 0.87
QT prolongation and Torsades de Pointes associated with clarithromycin. Am J Med (1998) 0.85
Association of intravenous erythromycin and potentially fatal ventricular tachycardia with Q-T prolongation (torsades de pointes). BMJ (1990) 0.85
Clarithromycin associated with torsades de pointes. Jpn Circ J (1999) 0.83
The effects of erythromycin on the electrocardiogram. Chest (1999) 0.82
Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. Pacing Clin Electrophysiol (1999) 0.80
Potentially fatal interaction between azithromycin and disopyramide. Pacing Clin Electrophysiol (2000) 0.79
Roxithromycin in prevention of acute coronary syndrome associated with Chlamydia pneumoniae infection: a randomized placebo controlled trial. J Med Assoc Thai (2001) 0.79
Erythromycin-induced QT prolongation and polymorphic ventricular tachycardia (torsades de pointes): case report and review. Clin Infect Dis (1994) 0.79
Erythromycin pharmacokinetics in man. J Int Med Res (1980) 0.78
[QT prolongation and circulatory arrest after an injection of erythromycin in a newborn infant]. Arch Fr Pediatr (1991) 0.78
Potentially fatal interaction between erythromycin and disopyramide. Am J Med (1989) 0.78
Torsades de pointes associated with antimicrobial therapy for pneumonia. Chest (1990) 0.77
Effect of erythromycin on myocardial repolarization in patients with community-acquired pneumonia. South Med J (1999) 0.76
[Torsade de pointes induced by the combination lidocaine-erythromycin and hepatic insufficiency]. Presse Med (1985) 0.76
[Peroperative circulatory arrest after intravenous injection of erythromycin lactobionate]. Ann Fr Anesth Reanim (1988) 0.76
Erythromycin induced Torsades de Pointes: case report and review of the literature. S D J Med (1994) 0.76
[Attack of torsades de pointes induced by an intravenous injection of erythromycin lactobionate]. Ann Fr Anesth Reanim (1988) 0.76
Erythromycin-induced torsades de pointes and ventricular fibrillation in a patient with Legionella pneumonia. Neth J Med (1994) 0.76
Azithromycin for prevention of exacerbations of COPD. N Engl J Med (2011) 8.66
Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med (2014) 3.51
Vitamin D levels and risk of acute exacerbations of chronic obstructive pulmonary disease: a prospective cohort study. Am J Respir Crit Care Med (2011) 2.64
Methodology for using long-term accelerometry monitoring to describe daily activity patterns in COPD. COPD (2009) 1.79
Utility of postoperative testing of implantable cardioverter-defibrillators. Pacing Clin Electrophysiol (2010) 1.51
Endocardial electrogram characteristics of epicardial ventricular arrhythmias. J Cardiovasc Electrophysiol (2013) 1.39
Azithromycin: We're there! Am J Respir Crit Care Med (2014) 1.07
Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2009) 0.99
Effect of catheter movement and contact during application of radiofrequency energy on ablation lesion characteristics. J Interv Card Electrophysiol (2013) 0.86
Utility of cardiac magnetic resonance imaging to differentiate cardiac sarcoidosis from arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol (2012) 0.86
Influence of lightweight ambulatory oxygen on oxygen use and activity patterns of COPD patients receiving long-term oxygen therapy. COPD (2012) 0.81
Synthetic opioids and arrhythmia risk: a new paradigm? Expert Opin Pharmacother (2012) 0.81
Ranolazine for the suppression of ventricular arrhythmia: a case series. Ann Noninvasive Electrocardiol (2014) 0.78
The NHLBI COPD clinical research network. Pulm Pharmacol Ther (2004) 0.78
Tumour necrosis factor receptor-75 and risk of COPD exacerbation in the azithromycin trial. Eur Respir J (2013) 0.76
Use of stored implanted cardiac defibrillator electrograms in catheter ablation of ventricular fibrillation. Pacing Clin Electrophysiol (2012) 0.75
Azithromycin and COPD Exacerbations in the Presence or Absence of Symptoms or Active Treatment for Gastroesophageal Reflux. Chronic Obstr Pulm Dis (2014) 0.75
Images in cardiovascular medicine: a mobile tubular mass visualized by transesophageal echocardiography after successful lead extraction. Circulation (2011) 0.75
Serum bilirubin and the risk of chronic obstructive pulmonary disease exacerbations. Respir Res (2017) 0.75
Life-threatening ST-segment elevation without coronary artery disease. Arch Intern Med (2011) 0.75
COCATS 4 Task Force 3: Training in Electrocardiography, Ambulatory Electrocardiography, and Exercise Testing. J Am Coll Cardiol (2015) 0.75
The irregular tachycardia that was not atrial fibrillation. Arch Intern Med (2011) 0.75